EMG
TPST icon

Ellington Management Group’s Tempest Therapeutics TPST Stock Holding History

Ellington Management Group’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-6
Closed -$125K – 804
2016
Q3 		$125K Buy
+6
New +$109K 0.03% 598

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ellington Management Group's TPST Position: Q4 2016 in Review

Ellington Management Group sold out of Tempest Therapeutics (TPST) in Q4 2016, closing a stake of 6 shares — an estimated $125K sold.

Ellington Management Group first reported a position in TPST in Q3 2016 and held it in 1 quarter. The position peaked at $125K in Q3 2016. 84 funds tracked by Wall St. Rank hold TPST as of Q4 2016.

  • Ellington Management Group reported no remaining Tempest Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Ellington Management Group sold 6 Tempest Therapeutics shares in Q4 2016, an estimated $125K.
  • Ellington Management Group first reported a position in Tempest Therapeutics in Q3 2016 and held it in 1 quarter.
  • Ellington Management Group's Tempest Therapeutics position peaked at $125K in Q3 2016.
  • 84 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2016.

Based on Ellington Management Group's 13F filing for Q4 2016, filed 14 Feb 2017.